Avoid concomitant use of tucatinib with CYP3A substrates, wherever negligible focus modifications could bring on critical or everyday living-threatening toxicities. If unavoidable, reduce CYP3A substrate dose Based on item labeling.Even so, you will have a relapse of despair should you end taking your antidepressant. Tell your physician right away